Published in Medical Letter on the CDC and FDA, July 27th, 2003
"The recombinant interleukin-1 receptor antagonist, anakinra (Kineret; Amgen Inc, Thousand Oaks, CA), has been approved by the US Food and Drug Administration and the European Commission for the treatment of patients with active rheumatoid arthritis (RA). Approval was granted following the extensive evaluation of anakinra in five pivotal clinical trials that assessed its efficacy and safety in RA patients," scientists in the United States and Germany report.
"These studies have indicated that anakinra has a favorable risk-benefit profile, producing rapid and sustained...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.